[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338519-105":59,"doc-detail-338519-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mir-449-identified-through-antiandrogen-exposure-mitigates-functional-biomarkers-associated-with-ovarian-cancer-risk-read-online","miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk - read online","","Androgen receptor (AR) signaling is implicated in epithelial ovarian cancer, but the mechanisms and effectiveness of anti-androgen agents such as flutamide remain unclear. This study examined flutamide’s impact on microRNA expression in women at high risk (HR) for ovarian cancer by comparing untreated HR, flutamide-treated HR, and low-risk (LR) controls. Flutamide normalized miRNA levels in HR tissues and strongly increased the miR-449 family. Functional assays in ovarian epithelial cells and cancer cell lines showed that miR-449 mimics suppressed AR and CSF1R, reduced migration, and supported flutamide’s chemopreventive potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mir-449-identified-through-antiandrogen-exposure-mitigates-functional-biomarkers-associated-with-ovarian-cancer-risk-read-online/338519/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mir-449-identified-through-antiandrogen-exposure-mitigates-functional-biomarkers-associated-with-ovarian-cancer-risk-read-online/338519.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about flutamide and ovarian cancer risk?","Question",{"text":112,"@type":113},"It investigates how flutamide may prevent ovarian cancer by identifying changes in microRNA expression and their downstream effects on functional biomarkers linked to risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the study cohorts defined?",{"text":117,"@type":113},"Ovarian and tubal tissues were collected from untreated high-risk (HR) women, flutamide-treated HR women, and low-risk (LR) controls, using three predefined cohorts from a phase 2 study.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does miR-449 play in the proposed mechanism?",{"text":121,"@type":113},"Flutamide upregulated the miR-449 family, and introducing miR-449 mimics reduced AR and CSF1R mRNA and protein levels while inhibiting ovarian cancer cell migration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338519,1790339399,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nmiR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk  \nXia Wang1,2, Ho-Hyung Woo3,6, Michelle Wei2, Steven Gibson3,6, Mitzi Miranda3,6, Demaretta Rush4, Janiel Cragun3,6, Wenxin Zheng5, Guang Yao2,6􀀍 &  \nSetsuko K. Chambers3,6􀀍  \nThe involvement of the androgen receptor (AR) pathway in developing epithelial ovarian cancer is increasingly acknowledged. However, the specific mechanisms by which anti-androgen agents, such as flutamide, may prevent ovarian cancer and their efficacy remain unknown. This study was initiated by investigating the impact of flutamide on miRNA expression in women at high risk (HR) for ovarian cancer. Ovarian and tubal tissues, free from ovarian, tubal, peritoneal cancers, and serous tubal intraepithelial carcinoma (STIC), were collected from untreated and flutamide-treated HR women as well as low-risk (LR) women controls. We performed miRNA sequencing on these 3 sample cohorts and observed that flutamide normalized miRNA levels in HR tissues, notably upregulating the miR-449 family to levels seen in LR tissues. In subsequent tests in primary ovarian epithelial cells and ovarian cancer cell lines (SKOV3 and Hey), flutamide also increased miR-449a and miR-449b-5p levels. Introducing mimics ofthese miRNAs reduced the mRNA and protein levels ofAR and colonystimulating factor 1 receptor (CSF1R, also known as c-fms), both of which are known contributors to ovarian cancer progression, with emerging evidence also supporting their roles in ovarian cancer initiation. Ovarian cancer cell migration was inhibited upon introducing miR-449a and miR-449b- 5p mimics. Together, our study suggests a novel dual-inhibitory mechanism of flutamide on theAR pathway (AR expression suppression in addition to direct androgen antagonism) and supports its chemopreventive potential in ovarian cancer, especially for HR patients with low miR-449 expression.  \nKeywords MicroRNA, CSF1R, Androgen receptor, Flutamide, Ovarian cancer risk  \nAbbreviations  \nAR Androgen Receptor  \nBMI Body Mass Index  \nBRCA1/2 Breast Cancer 1/2, early onset (genes) CSF1 Colony-Stimulating Factor 1  \nCSF1R Colony-Stimulating Factor 1 Receptor FFPE Formalin-Fixed, Paraffin-Embedded  \nGAPDH Glyceraldehyde-3-Phosphate Dehydrogenase hEGF human Epidermal Growth Factor  \nHR High-Risk  \nIIT Investigator-Initiated Trials  \nLR Low-Risk  \nmiR microRNA  \nqRT-PCR Quantitative Reverse Transcription Polymerase Chain Reaction STIC Serous Tubal Intraepithelial Carcinoma  \n1College of Animal Science and Technology, Northwest A&F University, Shaanxi, China. 2Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ, USA. 3Department of Obstetrics and Gynecology, University of Arizona, Tucson, AZ, USA. 4Department of Pathology, University of Arizona, Tucson, AZ, USA. 5Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 6University of Arizona Cancer Center, Tucson, AZ, USA. 􀀍 email: [guangyao@arizona.edu](guangyao@arizona.edu); [schambers@uacc.arizona.edu](schambers@uacc.arizona.edu)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nPost-transcriptional RNA regulation, including the crucial role of microRNAs (miRNAs), is pivotal in modulating gene expression with profound impacts on various cellular activities. Translation of our basic posttranscriptional RNA research1–4 to the pursuit of risk stratification and prevention potential for women who are at HR for developing ovarian cancer5–8 underlies the foundation of this report.  \nThis study was informed by our previous in vitro and in vivo findings that underscored the potential role of androgen signaling and AR pathway in epithelial ovarian cancer development9, which steered us towards evaluating anti-androgens, such as flutamide, as a potential preventive measure for HR women. Furthering this lin","cbCaivGStjnJFxag","https://ap.wps.com/l/cbCaivGStjnJFxag","pdf",2419447,12,"English","# Background and Rationale\n## Study overview and cohorts\n# Methods and Clinical Context\n## Biospecimen collection and miRNA profiling\n## Prior biomarker observations\n# Study Aims","[{\"question\":\"What question does the study address about flutamide and ovarian cancer risk?\",\"answer\":\"It investigates how flutamide may prevent ovarian cancer by identifying changes in microRNA expression and their downstream effects on functional biomarkers linked to risk.\"},{\"question\":\"How were the study cohorts defined?\",\"answer\":\"Ovarian and tubal tissues were collected from untreated high-risk (HR) women, flutamide-treated HR women, and low-risk (LR) controls, using three predefined cohorts from a phase 2 study.\"},{\"question\":\"What role does miR-449 play in the proposed mechanism?\",\"answer\":\"Flutamide upregulated the miR-449 family, and introducing miR-449 mimics reduced AR and CSF1R mRNA and protein levels while inhibiting ovarian cancer cell migration.\"}]","miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk - read online | PDF",1790024012,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc7ae0e61cc5e2060bf75c9c37fd00e9.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4eb0b68a89ec6d392baf428bb9bfe20d.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd7994acd73acc0bc5edbb90e367996c.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/510e55a60cda9cc471fdb0eee6c71c00.webp",980,1287]